Dorsomorphin (Compound C) 2HCl
(Synonyms: BML-275 2HCl,Compound C 2HCl) 目录号 : GC12560IC50:Dorsomorphin 以剂量依赖性方式抑制 BMP4 诱导的 BMP 反应性 SMAD 磷酸化(半数最大抑制浓度 (IC50) =0.47 mM)。
Cas No.:1219168-18-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
Kinase experiment [1]: | |
AMPK partial purification and in vitro kinase assay |
Liver AMPK is partially purified from male SD rats to the blue-Sepharose step. The 100-μl reaction mixture contains 100 μM AMP, 100 μM ATP (0.5 μCi 33P-ATP per reaction), and 50 μM SAMS in a buffer (40 mM HEPES, pH 7.0, 80 mM NaCl, 0.8 mM EDTA, 5 mM MgCl2, 0.025% BSA, and 0.8 mM DTT). The reaction is initiated with addition of the enzyme. After 30-minute incubation at 30°C, the reaction is stopped by addition of 80 μl 1% H3PO4. Aliquots (100 μl) are transferred to 96-well MultiScreen plates. The plate is washed three times with 1% H3PO4 followed by detection in a Top-count. The in vitro AMPK inhibition data obtained with compound C — (6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyyrazolo[1,5-a] pyrimidine — are fit to the following equation for competitive inhibition by nonlinear regression using a least-squares Marquardt algorithm in a computer program written by N. Thornberry of Merck Research Laboratories: Vi/Vo = (Km + S)/[S + Km × (1 + I/Ki)], where Vi is the inhibited velocity, Vo is the initial velocity, S is the substrate (ATP) concentration, Km is the Michaelis constant for ATP, I is the inhibitor (compound C) concentration, and Ki is the dissociation constant for compound C. |
Cell experiment [2]: | |
Cell lines |
mouse pulmonary artery smooth muscle cells (PASMCs), Hep3B cells |
Preparation method |
The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
0.1-20 μM for 30 min |
Applications |
Dorsomorphin (4 μM) inhibited osteogenic differentiation in C2C12 cells and suppressed BMP-mediated SMAD activation by blocking BMP type I receptor function. Moreover, treatment with dorsomorphin (1 μM) blocked BMP- and HJV-mediated hepcidin expression in cultured hepatoma-derived cells. |
Animal experiment [2]: | |
Animal models |
Zebrafish embryos model; Wild-type (WT) C57BL/6 adult mice model |
Dosage form |
10 mM dorsomorphin for 30 h; or 10 mg/ kg, intraperitoneal injection |
Applications |
Dorsomorphin induced dorsalization in zebrafish embryos model. Moreover, Dorsomorphin inhibited bone mineralization in vivo. Additionally, Dorsomorphin (10 mg/ kg) induced hyperferremia in mice. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: 1. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J. and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108, 1167-1174 2. Yu, P. B., Hong, C. C., Sachidanandan, C., Babitt, J. L., Deng, D. Y., Hoyng, S. A., Lin, H. Y., Bloch, K. D. and Peterson, R. T. (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 4, 33-41 |
IC50: Dorsomorphin inhibited BMP4-induced phosphorylation of BMP-responsive SMADs in a dose-dependent manner (half maximal inhibitory concentration (IC50) =0.47 mM).
Bone morphogenetic protein (BMP) signals coordinate developmental patterning and have essential physiological roles in mature organisms. The first known small-molecule inhibitor of BMP signaling, dorsomorphin, were identified in a screen for compounds that perturb dorsoventral axis formation in zebrafish.
In vitro: Previoius researchers found that dorsomorphin selectively inhibits the BMP type I receptors ALK2/ALK3/ALK6 leading to block BMP-mediated SMAD1/5/8 phosphorylation, osteogenic differentiation as well as target gene transcription. Using dorsomorphin, they examined the role of BMP signaling in iron homeostasis.dorsomorphin inhibited the systemic iron regulator hepcidin BMP-, hemojuvelin- and interleukin 6–stimulated expression, indicating that BMP receptors regulate hepcidin induction by all of these stimuli [1].
In vivo: The systemic challenge with iron rapidly induced SMAD1/5/8 phosphorylation and hepcidin expression in the liver, while dorsomorphin treatment could blocke SMAD1/5/8 phosphorylation, normalize hepcidin expression and increase serum iron levels. These suggest an crucial physiological role for hepatic BMP signaling in iron-hepcidin homeostasis [1].
Clinical trial: Dorsomorphin is still in preclinical development stage and no clinicl trial is ongoing currently.
Reference:
[1] Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, Lin HY, Bloch KD, Peterson RT.Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008;4(1):33-41.
IC50:Dorsomorphin 以剂量依赖性方式抑制 BMP4 诱导的 BMP 反应性 SMAD 磷酸化(半数最大抑制浓度 (IC50) =0.47 mM)。
骨形态发生蛋白 (BMP) 信号协调发育模式和在成熟生物体中具有重要的生理作用。第一个已知的 BMP 信号转导小分子抑制剂 dorsomorphin 在筛选干扰斑马鱼背腹轴形成的化合物时被鉴定出来。
体外:Previioius 研究人员发现,dorsomorphin 选择性抑制 BMP I 型受体 ALK2/ALK3/ALK6,从而阻断 BMP 介导的 SMAD1/5/8 磷酸化、成骨分化以及靶基因转录。他们使用 dorsomorphin 检查了 BMP 信号在铁稳态中的作用。dorsomorphin 抑制全身铁调节剂铁调素 BMP-、血幼素和白细胞介素 6 刺激的表达,表明 BMP 受体通过所有这些刺激调节铁调素诱导 [1]。
在体内:铁的全身性刺激会迅速诱导肝脏中的 SMAD1/5/8 磷酸化和 hepcidin 表达,而 dorsomorphin 治疗可以阻断 SMAD1/5/8 磷酸化,使 hepcidin 表达正常化并增加血清铁水平。这些表明肝脏 BMP 信号转导在铁-铁调素稳态中的重要生理作用 [1]。
临床试验:Dorsomorphin尚处于临床前开发阶段,目前尚无临床试验。
Cas No. | 1219168-18-9 | SDF | |
别名 | BML-275 2HCl,Compound C 2HCl | ||
化学名 | 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine;dihydrochloride | ||
Canonical SMILES | C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC=C5)N=C3.Cl.Cl | ||
分子式 | C24H25N5O.2HCl | 分子量 | 472.41 |
溶解度 | ≥100mg/mL in Water, ≥ 5.9mg/mL in DMSO, ≥ 11.34 mg/mL in 0.9% NS | 储存条件 | Store at -20°C,protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1168 mL | 10.584 mL | 21.1681 mL |
5 mM | 0.4234 mL | 2.1168 mL | 4.2336 mL |
10 mM | 0.2117 mL | 1.0584 mL | 2.1168 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。